627 related articles for article (PubMed ID: 32235097)
21. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition.
Koshy AG; Daver NG; Fathi AT
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101220. PubMed ID: 33279176
[TBL] [Abstract][Full Text] [Related]
22. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
24. New approaches for the immunotherapy of acute myeloid leukemia.
Geiger TL; Rubnitz JE
Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic targeting of surfaceome heterogeneity in AML.
Bordeleau ME; Audemard É; Métois A; Theret L; Lisi V; Farah A; Spinella JF; Chagraoui J; Moujaber O; Aubert L; Khakipoor B; Mallinger L; Boivin I; Mayotte N; Hajmirza A; Bonneil É; Béliveau F; Pfammatter S; Feghaly A; Boucher G; Gendron P; Thibault P; Barabé F; Lemieux S; Richard-Carpentier G; Hébert J; Lavallée VP; Roux PP; Sauvageau G
Cell Rep; 2024 Jun; 43(6):114260. PubMed ID: 38838225
[TBL] [Abstract][Full Text] [Related]
27. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitors in AML-A New Frontier.
Thummalapalli R; Knaus HA; Gojo I; Zeidner JF
Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893
[TBL] [Abstract][Full Text] [Related]
29. The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands.
Maurer S; Zhong X; Prada BD; Mascarenhas J; de Andrade LF
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555547
[TBL] [Abstract][Full Text] [Related]
30. Immune-Based Therapies in Acute Leukemia.
Witkowski MT; Lasry A; Carroll WL; Aifantis I
Trends Cancer; 2019 Oct; 5(10):604-618. PubMed ID: 31706508
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
Stahl M; Goldberg AD
Curr Oncol Rep; 2019 Mar; 21(4):37. PubMed ID: 30904967
[TBL] [Abstract][Full Text] [Related]
32. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia.
Vadakekolathu J; Rutella S
Blood; 2024 Jun; 143(26):2689-2700. PubMed ID: 37467496
[TBL] [Abstract][Full Text] [Related]
33. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments.
Leufven E; Bruserud Ø
Curr Med Chem; 2019; 26(28):5244-5261. PubMed ID: 30907305
[TBL] [Abstract][Full Text] [Related]
35. Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways.
Taghiloo S; Asgarian-Omran H
Crit Rev Oncol Hematol; 2021 Jan; 157():103164. PubMed ID: 33271388
[TBL] [Abstract][Full Text] [Related]
36. The potential role of the thymus in immunotherapies for acute myeloid leukemia.
Hino C; Xu Y; Xiao J; Baylink DJ; Reeves ME; Cao H
Front Immunol; 2023; 14():1102517. PubMed ID: 36814919
[TBL] [Abstract][Full Text] [Related]
37. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
39. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
[TBL] [Abstract][Full Text] [Related]
40. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N; Alotaibi AS; Bücklein V; Subklewe M
Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
